Send us Fan Mail

Jesse Mendelsohn and Michael Grosberg from Model N discuss why U.S. pricing complexity is spreading globally, the collapse of the PBM rebate model, what's really driving the pharmaceutical manufacturing boom, and why direct-to-consumer discount programs won't solve America's drug access problem.

00:00 Introduction to Life Science Success Podcast
00:34 Pressing Issues in Pharmaceutical Manufacturing
00:51 Introducing the Experts from Model N
03:08 Understanding International Reference Pricing
04:14 Impact of US Pricing on Global Drug Launches
09:26 Challenges with Pharmacy Benefit Managers
16:29 Domestic Manufacturing Boom in Pharmaceuticals
23:08 AI in Drug Discovery and Personalized Medicine
29:03 Access and Policy Discussion
30:01 Direct to Consumer Pricing
31:32 TrumpRx Overview
33:11 Compliance Challenges
38:30 Pharmaceutical Revenue Management
41:38 AI in Life Sciences
48:35 Future of Life Sciences
50:45 Concerns and Challenges
53:52 Excitement in Current Work
55:54 Conclusion and Final Thoughts

Send us Fan Mail

In this episode of the Life Science Success Podcast my guest is Troy Fugate. The CCO of Compliance Insight, Inc., Troy brings 30+ years of FDA readiness, GMP, and quality leadership—turning complex requirements into practical, culture-shaping solutions and championing the Align–Apply–Adapt framework used across pharma, cell and gene therapy, and medical devices.

00:00 Introduction to Life Science Success Podcast

00:37 Meet Troy Fugate: CCO of Compliance Insight

01:09 Troy's Career Journey and FDA Focus

04:10 The Align, Apply, Adapt Framework

04:47 Differentiating Compliance Insight

08:03 The Importance of Clarity in Compliance

17:10 Challenges and Solutions in Compliance

25:38 Human Behavior and Continuous Improvement

34:39 Troy's Inspirations and Concerns

39:07 Final Thoughts and Closing Remarks

Send us Fan Mail

In this episode of the Life Science Success Podcast my guest is Lyle Small, a seasoned innovator with 35 years of experience in interactive inks and coatings who is now the Founder and CEO of Lahjavida, Inc., a promising cancer research company developing targeted chemotherapy technologies. Lyle has an impressive track record of technological innovation, having previously founded Chromatic Technologies and developed groundbreaking color-changing technologies for brands like Coors Light, and is now focused on creating potentially transformative cancer treatments.

00:00 Introduction to Life Science Success Podcast
00:40 Celebrating Podcast Achievements
01:27 Interview with Lyle Small: Background and Journey
02:43 Lyle's Early Career and Innovations
07:13 Founding Chromatic Technologies Inc. (CTI)
09:00 CTI's Impact and Innovations
15:13 Transition to Lahjavida: New Ventures in Cancer Research
20:16 Challenges and Insights in Cancer Research
25:03 Understanding Success Rates in Business
27:40 The Importance of Failure Mode and Effects Analysis (FMEA)
28:58 Building Effective Teams: Lessons Learned
38:27 Leadership Qualities and Challenges
40:39 Current Endeavors and Fundraising Efforts
43:45 Inspiration, Concerns, and Excitement
48:05 Conclusion and Final Thoughts

Send us Fan Mail

This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic initiatives in the realms of artificial intelligence and machine learning within the life sciences sector. With an impressive background that bridges technology and life sciences, Elizabeth has been instrumental in the formation and launch of the GenAI Council, an innovative effort aimed at harnessing generative AI to revolutionize research and development in life sciences.

• Introduction of Guests and Focus: Don, a consultant in life sciences, introduces Elizabeth Smalley, VP of Product Management, Data, and Analytics at ArisGlobal. The discussion emphasizes the transformative power of generative AI (GenAI) in the life sciences sector, with a particular focus on Elizabeth's leadership in strategic AI initiatives at ArisGlobal.

• Elizabeth Smalley's Background and Journey: Elizabeth recounts her diverse experience in product management across e-commerce, manufacturing, and healthtech. Her story highlights the central role of AI in her career, including significant achievements in developing AI-driven clinical solutions at Teladoc Health and her progression to leading ArisGlobal's data, analytics, and AI strategies.

• ArisGlobal's Innovations and Role: The conversation explores ArisGlobal's impact on life sciences, especially its innovative use of AI in pharmacovigilance and regulatory processes. Elizabeth points out ArisGlobal's pioneering introduction of AI into case processing workflows and its leadership in adopting generative AI, aiming to enhance efficiency and patient safety in the sector.

• Generative AI: Challenges and Opportunities: Elizabeth discusses the economic potential of generative AI in life sciences, acknowledging regulatory challenges and the necessity of industry-wide collaboration to navigate these. She emphasizes the importance of creating a responsible AI adoption playbook, addressing transparency, and fostering innovation within a regulatory framework.

• Vision for the Future: The interview concludes with a forward-looking view on how generative AI could revolutionize patient care, streamline drug development, and optimize regulatory compliance. Elizabeth advocates for a collaborative approach to leverage AI responsibly, aiming to improve health outcomes, enhance operational efficiencies, and ensure patient safety in the evolving landscape of life sciences.

Send us Fan Mail

This week on the Life Science Success Podcast, my guest is Dr. Tiago Reis Marques Dr. Marques is a psychiatrist and currently the Chief Executive Officer of Pas i thea Therapeutics. Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome.

On this episode of Life Science Success, Don Davis interviews Dr. Tiago Reis Marques, the CEO of PACEA Therapeutics. They discuss Dr. Marques's journey in psychiatry, the company's focus on CNS disorders, their pipeline of drugs targeting neurological conditions like schizophrenia and ALS, and the impact of their research on rare disorders like neurofibromatosis type one. The conversation also touches on leadership advice, inspiration, concerns about global issues, and what excites them.

• Dr. Tiago Reis Marques, a psychiatrist, is the CEO of Pasithea Therapeutics, a company focused on central nervous system (CNS) disorders. His background in medical research and his transition from academia to biotech were driven by a desire to apply his knowledge to develop treatments that benefit patients.
• Pasithea Therapeutics, co-founded with Professor Steinman from Stanford, aims to create innovative therapies for unmet needs in CNS disorders. The company's approach balances new drugs targeting novel mechanisms of action with known drugs repurposed for new applications.
• One of the company's focuses is on neurofibromatosis type one, a disorder affecting around 100,000 patients in the US, highlighting the company's commitment to tackling rare and challenging diseases with significant unmet needs.
• Marques emphasizes the importance of precision psychiatry and targeting specific subtypes of disorders, drawing parallels to how cancer treatments have evolved to focus on specific biomarkers and subtypes, reflecting a broader trend towards personalized medicine.
• His experiences and work in brain imaging, specifically with positron emission tomography (PET) and psychopharmacology, underscore his multidisciplinary approach to understanding and treating CNS disorders, leveraging his academic background to inform his leadership and strategic direction at Pasithea Therapeutics.

Send us Fan Mail

In the interview, Don Davis PhD, MBA talks to Toban Zolman about his company, Kivo. Zolman takes us through his impressive journey of over 20 years in life sciences and the transformation he has witnessed in the industry. He further details the services of Kivo, stating that the company helps businesses involved in life sciences, specifically those developing clinical trials for pharmaceutical, medical device, and biotech companies, to streamline and optimize their processes. 

He specifically speaks about the significant shift in the industry from large pharmaceutical companies running drug trials to now being dominated by smaller companies without a product in the market yet. Regarding emerging trends, Zolman anticipates artificial intelligence will have a transformational impact on the industry. He also highlights the importance of knowing when to say "no" and making definitive decisions based on customer's needs, aligning company focus to customer growth, and maintaining transparency in their operations.

5 Key Points: 

• Toban Zolman is the CEO of Kivo, with over 20 years of leadership experience in developing, deploying, and validating computerized systems for clinical trials.
• Zolman's career began in the early 2000s at an electronic submission company, pioneering the transition from paper to electronic submissions for pharmaceutical companies globally, impacting 47 out of the top 50 Pharma companies in 16 countries.
• At Kivo, Zolman leverages his extensive background to innovate in life sciences by integrating technology and regulatory best practices to support emerging companies in developing and marketing new drugs efficiently.
• Kivo stands out in the life sciences space by blending deep clinical and regulatory experience with enterprise SaaS expertise, offering a unique approach to accelerating drug development and approval processes.
• Zolman emphasizes the importance of adaptability, saying no to maintain focus, and the potential transformative impact of AI on drug development, viewing it as both an intimidating and exciting challenge for the future.

Send us Fan Mail

Revolutionizing Patient and Physician Experiences through Digital First Strategies - In this week's episode of Life Science Success, we dive into the intersection of digital innovation and healthcare commercialization with leaders from Indegene, a company revolutionizing patient and physician experiences through digital-first strategies. We'll explore the journeys of Nancy Phelan, a biopharma commercial strategy expert; Jeff Rothstein, a marketing visionary who has significantly expanded Indegene's brand and capabilities; and Kevin Patterson, a strategic thinker in medical solutions, as they share insights on driving healthcare forward in today's complex landscape.

Key Takeaways:

1. Interdisciplinary Innovation: The convergence of diverse backgrounds and expertise is driving innovation in healthcare, emphasizing the importance of storytelling and engagement in healthcare marketing.
2. Digital Transformation: The shift towards digital and data-driven strategies is revolutionizing patient and physician experiences, making healthcare more personalized and accessible.
3. AI's Growing Influence: Artificial intelligence is poised to transform healthcare delivery and treatment, with current applications representing just the tip of the iceberg.
4. Navigating Market Access Challenges: Successfully bringing new treatments to market requires overcoming regulatory and accessibility hurdles, highlighting the need for strategic market access planning.
5. Optimism for the Future: Despite challenges, there's a strong sense of optimism about the future of healthcare, driven by technological advancements and a commitment to improving patient care.

Send us Fan Mail

This week on Life Science Success, we're excited to welcome Donald Zinn, a seasoned professional with nearly three decades of experience in the biotech, pharmaceutical, and medical device industries. Beyond his executive roles, Don contributes to the National Institutes of Health (NIH) as a Commercialization Grant Reviewer and has played a pivotal role at Crossject, leading their needle-free auto-injector platform to global success since the onset of COVID.

• Donald Zinn's Background and Experience: Donald Zinn, the Vice President of US Business at Crossject, has nearly 30 years of experience in the life sciences industry. He started his career with an undergraduate degree from UMBC and went on to innovate in the field by inventing dry process microarray during his time at the Uniform Services University. His journey included roles such as lab manager at Georgetown University's HIV Center, and leadership positions in companies focused on oncology, infectious diseases, and more.

• Crossject's Needle-Free Auto Injector: Zinn is part of the Crossject team, working on a needle-free auto injector, which he finds to be an exciting and innovative technology. This device is designed to deliver medications quickly and without the need for needles, addressing needle phobia and improving patient compliance.

• Demonstration of the Injector's Ease of Use: During the podcast, a demonstration was discussed showing how the injector works, including its ability to administer medication through clothing. This feature is particularly advantageous in emergency situations where speed and ease of use are critical.

• Focus on Partnerships and Market Expansion: Zinn emphasizes the importance of finding the right partners worldwide to distribute Crossject's needle-free injector. The company aims to select partners based on their expertise and market presence to ensure the technology is accessible to a broad audience.

• Future Prospects and Industry Impact: The conversation highlighted the potential of Crossject's technology to revolutionize drug delivery, especially for emergency medications like epinephrine. The ease of use, coupled with the effectiveness of the needle-free injector, presents a significant advancement in patient care and medication administration.

Send us Fan Mail

In this episode of Life Science Success, my guest is Dr. Kate Broderick. Dr. Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery fields. She also actively works with teams at TriLink BioTechnologies, a Maravai company, to advance its global reagents and manufacturing services.

• Dr. Kate Broderick's Background: Originally from Scotland, Kate Broderick's academic journey began with using animals as models for human diseases. Her passion lies at the intersection of science and clinical application, leading her to focus on DNA therapeutics and drug delivery fields in the United States, particularly after her postdoctoral work at UCSD.
• Focus on DNA and RNA Technologies: Dr. Broderick is motivated by the fundamental roles of DNA and RNA in medicine. She discusses the potential of these molecules to revolutionize treatments, vaccines, and therapies, foreseeing a future where new medical solutions are developed using these technologies.
• Career Development and Innovation: Throughout her career, Dr. Broderick has embraced various roles beyond her scientific training, including clinical development and finance, which have enriched her understanding of product development and corporate strategy within biotech startups.
• Role as Chief Innovation Officer at Maravai: In her current role, Dr. Broderick emphasizes the importance of innovation in staying ahead in the fast-paced field of life sciences. She discusses fostering collaborative environments for scientists, integrating client needs into R&D, and focusing on structured innovation to drive the company's mission forward.
• Concerns and Future Outlook: Dr. Broderick expresses concerns about vaccine hesitancy and misinformation, emphasizing the need for better communication in the scientific community. She is excited about the future of nucleic acid medicines, predicting significant advancements in treating various diseases and developing new vaccines within the next decade.

Send us Fan Mail

In this episode of Life Science Success, my guest is Dr. Thomas Rademacher. Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation. He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur.

• Dr. Thomas Rademacher, MD, PhD, is the co-founder and CEO of Emergex, with a background as an Emeritus Professor of Molecular Medicine at the University College of London and a serial entrepreneur. His career has oscillated between academic and entrepreneurial roles, adhering to the philosophy of not staying in the same job for more than ten years.
• Rademacher's academic foundation in hardcore biochemistry was established during his PhD at the University of Wisconsin Madison. This rigorous training in biochemistry has been a cornerstone throughout his career, enabling him to navigate and innovate in the complex field of molecular medicine.
• His work has significantly contributed to the field of monoclonal antibodies, starting with foundational research at Oxford and involving the use of Chinese hamster ovary (CHO) cells. This work was pivotal for the development of recombinant proteins and monoclonal antibodies, leading to advancements in medicine.
• Rademacher has been involved in groundbreaking research and entrepreneurial ventures, including the Glycobiology Institute, which attracted interest from major corporations like Monsanto. His work has led to significant scientific advancements and the formation of companies that have had substantial impacts on the medical and biotechnological landscapes.
• He is currently focused on challenges in vaccinology and immunology, particularly in developing vaccines that activate the cellular immune response to fight viral infections effectively. Rademacher's innovative approach involves utilizing quantum-confined gold clusters and micro-needle technology to enhance vaccine delivery and efficacy.

Send us Fan Mail

Ronan O’Hagan, President & CEO, Bectas Therapeutics Inc.  Rónán is a founder and the President and Chief Executive Officer for Bectas Therapeutics Inc. He has over 20 years of experience in oncology R&D including bringing over 20 molecules through IND and into clinical development and helping to guide 4 drugs through clinical development to FDA approval.

• Ronan O'Hagan is the President and CEO of Bectas Therapeutics, a cancer drug discovery and development company with over 20 years of experience in oncology R&D. He has been instrumental in advancing over 20 molecules through IND (Investigational New Drug) to clinical development and guiding four drugs through clinical trials to FDA approval.
• His approach at Bectas Therapeutics focuses on utilizing insights from human patients' immune responses to develop precision therapies, aiming to find the right drug for the right patient. This approach stems from his belief that understanding cancer's complexity requires a deep understanding of patients themselves.
• O'Hagan's career includes significant roles in various organizations: Chief Scientific Officer at Apricity Health and Exilio Therapeutics, leader of the Oncology Discovery team at Merck Research Labs, and involvement in a biotech startup originating from Dana Farber Cancer Institute.
• He emphasizes the importance of values like focusing on patients, people, and proof of concept in drug development. He believes in balancing innovation with discipline and highlights the need for collaborative but strong leadership in the pharmaceutical industry.
• O'Hagan discusses the challenges and triumphs of drug development, stressing the importance of speed in bringing therapies to patients and the need for alignment around core values within a team. He also underlines the role of precision in enhancing the effectiveness of immune therapies and the necessity of inclusive research to benefit diverse patient populations.

Send us Fan Mail

In this episode of Life Science Success, my guest is Matt Hill, Ph.D.  Matt is founder and CEO of Elegen Corp., a privately-held company based in the San Francisco Bay Area committed to revolutionizing synthetic biology workflows with innovative DNA writing technology.

1. Background and Experience: Matt Hill has a Ph.D. in genetics from Stanford University and was initially attracted to the Bay Area for its vibrant startup ecosystem. After completing his Ph.D., he joined Nera, a leading molecular diagnostics company, where he contributed to product development and new capabilities, particularly in massively multiplex PCR technology.

2. Journey to Founding Elegen: Hill's experience at Nera, especially in DNA synthesis and production challenges, led him to identify DNA production as a critical bottleneck in life sciences. His interest in solving complex problems and connecting technology areas motivated him to found Elegen to address these challenges in DNA synthesis and production.

3. Elegen's Impact and Infinia DNA: Elegen's product, Infinia DNA, aims to streamline workflows in life sciences, providing researchers with faster, more accurate DNA synthesis. This technology impacts various fields, including therapeutics and synthetic biology, by enabling quicker and more efficient product development cycles.

4. Leadership and Vision: As a leader, Hill emphasizes inspiration, encouragement, and problem-solving. He discusses the importance of Elegen's technology in advancing fields like personalized therapeutics and its potential in addressing major health challenges. Hill also highlights the need for more investment in foundational research and development to foster scientific progress.

Send us Fan Mail

In this episode of Life Science Success, Ross Jackson, the guy who wrote two books about patient recruitment, is returning to tell us about his new patient recruitment book. Ross is a specialist in patient recruitment for clinical trials, having helped deliver many thousands of patient registrations for clients in the UK, Europe, and the US.

The key highlights from the interview:

• Ross Jackson is a specialist in patient recruitment for clinical trials with experience in the UK, Europe, and the US. He has authored two books on the subject.

• His career journey began in digital marketing, where he initially recruited patients for a doctor's new treatment. Over time, he shifted his focus to healthcare and clinical trial recruitment.

• Patient recruitment faces challenges related to awareness and access. Many people are unaware of clinical trials, and misconceptions like being seen as "guinea pigs" persist. Lack of understanding about the importance of clinical research compounds the issue.

• Ross Jackson's first book focused on using Facebook ads for patient recruitment. It aimed to make it easier for research sites and others to access potential trial participants effectively.

• His new book takes a unique approach, featuring a fictional character named Josh Black, a puzzle solver who tackles patient recruitment challenges. The book explores various aspects of patient recruitment and aims to make the topic more accessible and engaging.

• Ross emphasizes the need for collaboration within the industry and the potential impact of AI, particularly natural language processing, in improving patient recruitment processes.

• He also mentions his excitement about attending a conference and watching his first Super Bowl in Orlando, highlighting his interest in sports and the upcoming event.

• The interview concludes with gratitude for sharing information about his new book and the hope that it will benefit those interested in patient recruitment. The book is available on Amazon.

Send us Fan Mail

In this episode of the Life Science Success Podcast my guest is Lauri Befus, Vice President of Clinical Operations at M3 Wake Research, a leading integrated site network in the United States. With over 13 years of experience in clinical research and healthcare operations, Lauri brings a unique perspective to clinical trials, focusing on patient-centric strategies and operational excellence.

00:00 Introduction to Life Science Success Podcast
00:37 Meet Lauri Befus: Vice President of Clinical Operations at M3 Wake Research
00:59 Lauri's Journey into Clinical Research
01:53 Educational Background and Early Career
02:36 Career Progression and Key Milestones
04:25 Challenges in the Life Sciences Industry
05:18 Diversity and Inclusion in Clinical Trials
06:16 Overview of M3 Wake Research
07:37 Lauri's Role and Responsibilities
13:59 Innovative Projects and Initiatives
16:28 Future Goals and Industry Innovations
17:31 Leadership Insights and Advice
24:19 Conclusion and Final Thoughts

Send us Fan Mail

In this episode of Life Science Success, my guest is Dr. Lishan Aklog.  Dr. Aklog is the CEO of Lucid Diagnostics he also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception.

1. Dr. Lishan Aklog's Background: Dr. Aklog, CEO of Lucid Diagnostics and executive chairman of PAVmed’s subsidiary Varys Health, was a cardiothoracic surgeon with a strong interest in technological innovation in medicine. He has an extensive background in academic cardiac surgery and was actively involved in medical device innovation.

2. Transition to Entrepreneurship: Transitioning from a successful career in cardiac surgery, Dr. Aklog co-founded Lucid Diagnostics and PAVmed. He ventured into medical device entrepreneurship, focusing on developing and commercializing innovative technologies. He was instrumental in creating and selling medical devices, notably a device for non-surgically removing clots.

3. Lucid Diagnostics and Focus on Cancer Detection: Under Dr. Aklog’s leadership, Lucid Diagnostics specializes in early cancer detection, particularly esophageal cancer. Dr. Aklog emphasizes the importance of pre-cancer detection and prevention, highlighting the challenges in raising awareness and adherence to screening guidelines.

4. Challenges and Achievements: A significant challenge in Dr. Aklog's journey has been raising capital to bring innovative technologies to market. Despite these challenges, Lucid Diagnostics has made substantial progress, especially in gaining payer coverage and launching large-scale screening programs.

5. Leadership and Vision: Dr. Aklog's leadership philosophy centers on building a culture of success, teamwork, and innovation. He stresses the importance of surrounding oneself with talented individuals and working cohesively towards a shared mission, with a particular focus on impacting patient lives through advanced medical technologies.

Send us Fan Mail

In this episode of Life Science Success my guest is Roee Hevrony. Roee is the CFO of ImmunoBrain Checkpoint. Prior to joining IBC in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch.

• The podcast features an interview with Roee Hevrony, the CFO of ImmunoBrain Checkpoint.
• Roee Hevrony discusses his background, which includes growing up in Israel and working in investment banking before joining ImmunoBrain.
• ImmunoBrain is focused on a novel approach to treating neurodegenerative diseases by targeting the immune system rather than the brain itself.
• The company has been conducting research for nine years, expanding from basic research to clinical studies, with a unique therapy approach.
• Roee Hevrony emphasizes the importance of long-term vision and patience in the pharmaceutical industry, especially in the field of neurodegeneration.

Send us Fan Mail

In this episode of Life Science Success, my guest is Tom Hartman.  Tom is the President and CEO of the International Society of Pharmaceutical Engineering (ISPE), Tom leads a global network of 20,000+ professionals spanning the complete pharmaceutical lifecycle.

In this edition of Life Science Success, Don Davis interviews Tom Hartman, the president and CEO of the International Society of Pharmaceutical Engineering (ISPE). They discuss Hartman's career journey and the role of the ISPE in the life sciences industry. Hartman discusses the critical role of the society's volunteer network and emphasizes the importance of speed, quality, and solid decision-making in the industry. Concerns about industry shortages, workforce challenges, and readiness for future potential pandemics also arise. Hartman highlights several exciting incursions, such as the 'Facility of the Year Award' and ISPE's workforce of the future initiative. The interview sheds light on the ISPE's strategic goals and the overall current industry landscape and trends.

Send us Fan Mail

In this episode of the Life Science Success Podcast my guests are James Foster, CEO of Virax Labs and Nigel McCracken COO of Virax Labs.  Virax Labs is a global biotechnology company specializing in the development of innovative diagnostic solutions. They focus on T-cell testing and immune profiling, with a novel portfolio of FluoroSpot T-cell diagnostics aimed at indications associated with chronic inflammation and T-cell exhaustion.

• Podcast Overview: The first "Life Science Success" podcast episode in 2024 features James Foster, CEO, and Nigel McCracken, COO, of Virax Biolabs. 

• James Foster's Background: James Foster, CEO of Virax Biolabs, co-founded the company about 10 years ago. Initially starting in finance, he shifted to biotech and diagnostics due to his entrepreneurial interests, particularly influenced by the 2008 financial crisis. His goal is to develop comprehensive immune profiling in-vitro diagnostics (IVDs), focusing on early diagnosis of post-viral syndromes, chronic inflammation, and T-cell exhaustion.

• Virax Biolabs' Mission and Technology: Virax is dedicated to creating innovative diagnostic solutions, particularly their T-cell testing platform. This platform aims to address significant health issues like long COVID, affecting millions in the US and Europe. Foster emphasizes the importance of early detection in disease progression and the role of the immune system in combating pathogens.

• Nigel McCracken's Role and Insights: As COO, Nigel McCracken plays a crucial role in scaling Virax from a small team to a larger organization. He discusses the importance of strategic focus, effective decision-making, and the development of companion diagnostics, which are essential for personalized medicine, especially in oncology.

• Future Outlook and Challenges: Both Foster and McCracken highlight the challenges in biotech, including the need for innovation, execution, and efficient leadership. They foresee an increasing burden on healthcare systems due to post-viral syndromes and chronic conditions. The podcast also touches on the potential of venture capital in fostering new ideas and innovations in the biotech sector.

Send us Fan Mail

In this episode of Life Science Success, we are welcoming back Dr. AJ Mellott. Dr. Mellott is the CEO and Co-Founder, Ronawk manufacturer of customized tissue-mimetic technology that is advancing science.

1. Dr. AJ Mellott is the CEO and co-founder of Ronawk, a company that specializes in creating hydrogel substrates that mimic various tissues in the human or animal body.
2. Ronawk's tissue mimetic technology is used in cell culture to produce high-quality, active cells that are valuable for medical and diagnostic applications.
3. The company has recently expanded and moved to Overland Park, Kansas, and has experienced significant growth in its team and production practices.
4. Ronawk's technology has facilitated collaborations between researchers in different fields and has lowered barriers to experimentation and innovation in the life sciences.
5. Dr. Mellott is excited about the potential of AI and machine learning to streamline research processes and the personalized screening of therapies for patients, ultimately improving healthcare outcomes.

Send us Fan Mail

In this episode of Life Science Success, my guest is Dr Paul Song. Dr. Song has served as Chief Executive Officer and Vice Chairman of NKGen since December 2022.

1. Dr. Paul Song, CEO and Vice Chairman of NKGen since December 2022, shares his background as a radiation oncologist and his journey into biotech.
2. Dr. Song talks about the importance of natural killer cells in the body's defense against diseases and their potential in treating conditions like Alzheimer's.
3. NKGen's phase one trial showed promising results, with 90% of patients either stabilizing or improving in Alzheimer's treatment.
4. NKGen is also exploring the use of natural killer cells in combination with other cancer therapies to enhance their effectiveness while minimizing side effects.

Send us Fan Mail

In this episode of Life Science Success, we are talking about Securing America's Pharmaceutical Supply with David Sanders and Tony Paquin.  We are going to discuss derisking the supply chain and building resilience.

Don, is joined by guests, David Sanders and Tony Paquin. They discuss the importance and challenges of securing America's medical supply chain. David introduces himself as the Vice President of Government Affairs at Coherence Biosciences and Executive Director at Securing America's Medicine and Supply, and Tony as the CEO and co-founder of iRemedy Healthcare, an AI-driven supply chain platform. They delve into the impacts of the COVID-19 pandemic on these supply chains, their effort in repatriating pharmaceutical supply and manufacturing back in America, and the role of innovation in overcoming the costs and barriers involved. Tony also mentioned his book, "The End of Us," which talks about this same issue.

Send us Fan Mail

My guest today on the Life Science Success Podcast is Andrea Henderson.  Andrea is a Partner in the Life Sciences, Healthcare, Diversity, CEO & Board practices at DHR Global where she is an executive talent solutions strategist.

Andrea Henderson, an Executive Talent Solutions Strategist, and they delve into Andrea's career journey, which started with a passion for diplomacy and evolved into a focus on talent management and diversity in the corporate world.

Key Takeaways:

1. Operational Excellence: Don emphasizes the significance of operational excellence in the life sciences industry, particularly the importance of value stream mapping.

2. Career Evolution: Andrea's career journey highlights the unpredictable nature of career paths. Her transition from diplomacy to talent management and executive search underscores the importance of adaptability and problem-solving skills.

3. Diversity and Inclusion: Andrea discusses the role of diversity and inclusion in executive-level roles, emphasizing the need to consider a wide range of perspectives to build the best teams.

4. Impactful Leadership: Don and Andrea touch on leadership styles, with Andrea describing her leadership style as collaborative, visionary, and empowering. They also discuss the importance of authenticity, trust-building, and clear communication in leadership.

5. Championing Change: Andrea expresses her excitement about the various avenues available to impact the future, particularly in promoting diversity and creating a more inclusive corporate environment.

Send us Fan Mail

In this episode of Life Science Success, my guest is Sucheshna Patil.  She is the CEO and founder of MobilityZ Health. A health-focused biotech engineer, innovator, and researcher building health technology products.

1. Mobility Z Health's Focus: The company specializes in orthopedic care, particularly addressing the problem of delays in orthopedic appointments. Their goal is to provide early care and diagnosis for musculoskeletal injuries, reducing backlogs in orthopedic care.

2. Transition from Humans in Space: Although the company initially operated as "Humans in Space," it later transitioned to the name "Mobility Z Health" to better align with its focus on healthcare and orthopedic solutions.

3. Multifaceted Background: Sucheshna Patil has a background as a biotech engineer and researcher, with a passion for healthcare innovation. She drew from her experiences in healthcare, research, and engineering to develop solutions for musculoskeletal injuries.

4. User-Friendly Approach: Mobility Z Health places a strong emphasis on user experience and user-friendliness in its products to ensure that a wide range of people, including patients and older generations, can use them.

5. Development Stage: The company is currently in the alpha testing phase, with private access for patients and doctors who want to use the product. A beta version for broader consumer use is expected to launch in January.

Send us Fan Mail

In this episode of Life Science Success, my guest is Mara Holinger.  Mara is the SVP and co-founder of Quantum Regulatory Solutions.  She has extensive experience in assisting pharmaceutical and biotech firms with preparing their regulatory pathway, providing regulatory input for clinical trial designs and clinical development plans, performing gap analyses for preclinical testing and writing regulatory applications.

Key points covered in this interview: 

1. Background and Expertise: Mara Holinger has a strong background in Regulatory Affairs, with a Ph.D. in a related field. She also highlighted her co-founders' scientific expertise, making their team unique in the regulatory consulting field.

2. Client Base: Quantum Regulatory Solutions primarily serves small to midsize pharmaceutical companies, offering a range of services beyond just regulatory strategy, including pre-meeting support and long-term pathway planning.

3. Team Collaboration: Mara emphasized the importance of collaboration within her team, combining their diverse skill sets to provide comprehensive solutions to clients. This collaborative approach sets them apart from others in the field.

4. Leadership and Empowerment: She mentioned the value of strong leadership and role models who encouraged her to speak up and not apologize for her opinions. This empowerment has been crucial in her career.

5. Passion for Problem-Solving: What excites Mara is the opportunity to solve complex puzzles in the regulatory space, working closely with various stakeholders to ensure that innovative therapies can navigate the regulatory process successfully.

Send us Fan Mail

In this episode of the Life Science Success Podcast, my guest is Ashley Scholz, the Vice President of Marketing at Vector Laboratories, who brings over 16 years of experience in medical devices, diagnostics, and strategic marketing. With a proven track record of driving growth, building high-performing teams, and optimizing commercial strategies, Ashley shares her insights on innovation in the life sciences industry.

00:00 Introduction to Life Science Success Podcast
00:47 Meet Ashley Scholz: VP of Marketing at Vector Laboratories
01:21 Ashley's Career Journey and Experience
04:52 Transition to Vector Laboratories
06:16 Challenges and Learnings at WL Gore
13:10 Building High Performing Teams
16:08 Why Vector Labs?
21:36 Vector Labs' Mission and Future Focus
22:49 Marketing's Role in B2B Transition
25:24 Supporting Scientists and Researchers
26:35 Innovative Projects and AI Integration
29:31 Impact of Recent Acquisitions
31:12 Balancing Commercial Growth and Customer-Centricity
35:14 Leadership and Organizational Insights
38:56 Inspiration and Concerns
40:47 Excitement for Future Strategies
43:52 Conclusion and Final Thoughts

Send us Fan Mail

In this episode of Life Science Success, my guest is Cristian Massacesi MD.  Cristian is the Chief Medical Officer & Oncology Chief Development Officer at AstraZeneca.  In the interview, we will discuss his start in oncology, his career path, and current trends in oncology. 

1. Guest Introduction: Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca. The discussion focuses on his career in oncology, his path in the medical field, and current trends in technology.

2. Background and Career Path: Cristian Massacesi, originally from Italy, pursued a career in oncology due to its challenges and potential for impact. After training in Italy, the UK, and the USA, he transitioned from clinical practice to pharmaceutical research, realizing his passion for clinical research.

3. Role at AstraZeneca: In his dual role at AstraZeneca, Massacesi focuses on prioritizing tasks and managing a busy schedule. He works in R&D, particularly in oncology, overseeing the development of safe and effective products, and engaging with various teams globally.

4. Clinical Trials and Leadership: Massacesi emphasizes the importance of clinical trial diversity and the need for innovation in trial execution. He shares his perspective on leadership, highlighting the necessity of assembling strong teams and being accessible and human in management.

5. Vision and Challenges: He is driven by the goal of defeating cancer and leading an organization towards this aim. Massacesi expresses concerns about the complexity of change management in drug development and the regulatory environment, while also finding excitement in the advancements and recognition in the field.

Send us Fan Mail

In this episode of Life Science Success, my guest is Bob Rochelle the Chief Commercial Officer at Cleveland Diagnostics.  Bob is a proven expert in launch, strategy, and marketing for novel healthcare products. His more than 30 years of experience ranges from start-ups such as Exact Sciences and Good Start Genetics to established multinationals such as Abbott Laboratories.

1. Introduction of Bob Rochelle: The episode of "Life Science Success" features Bob Rochelle, Chief Commercial Officer at Cleveland Diagnostics. Rochelle is recognized for his expertise in launch strategy and marketing for novel healthcare products.

2. Bob Rochelle's Background: With 35 years in the healthcare industry, Rochelle has extensive experience, primarily in diagnostics, working with both pharmaceuticals and startups. His career includes roles in various therapeutic and diagnostic areas, from antibiotics and antihypertensive drugs to genetic disease diagnostics and cancer.

3. Transition to Startups: Rochelle discusses his transition from large corporations like Abbott Laboratories to smaller startups. He emphasizes the appeal of being able to rapidly implement ideas and the challenges of limited resources compared to larger companies.

4. Cleveland Diagnostics and Novel Technology: At Cleveland Diagnostics, Rochelle is involved with a novel platform technology for cancer diagnostics. He highlights the importance of innovative technology and a strong team in his career choices.

5. Insights on Cancer Diagnostics and Career Lessons: Rochelle shares insights on the evolution of cancer diagnostics, emphasizing the importance of specificity and sensitivity in tests like isopsa for prostate cancer. He reflects on lessons learned throughout his career, including the significance of diverse perspectives in small companies and the challenges of navigating healthcare reimbursement systems.

Send us Fan Mail

In this episode of Life Science Success, my guest is Todd Druley PhD.  Todd is the Chief Medical Officer at Mission Bio.  His expertise lies in translational genomic and computational tools to improve clinical diagnostics and apply these tools to disease-specific questions in cancer.

Key Takeaways:

1. Dr. Todd Druley is the Chief Medical Officer at Mission Bio, specializing in translational genomics and computational tools for clinical diagnostics, especially in cancer.
2. Dr. Druley's career was influenced by a personal connection to pediatric leukemia, leading him to bridge medicine and genomics research.
3. He transitioned from academia to industry, joining companies like Archer DX and Mission Bio to have a broader impact in diagnostics and treatment.
4. Dr. Druley emphasizes the importance of single-cell multiomics in diagnostics and bridging the gap between technical advancements and clinical treatments in pediatric oncology.

Send us Fan Mail

In this episode of Life Science Success, my guest is Kalyan Obalampalli.  Kalyan is a disruptor and technology innovator with over 20 years of experience in leadership positions in clinical operations and outsourcing at major pharma and biotechs. Kalyan is the founder and president of Clin.AI, a disruptive start-up that is revolutionizing the way vendor selection and management is conducted in the industry.

1. Introduction of Kalyan Obalampalli (KO): KO is a disruptor and technology innovator with over 20 years of experience in leadership positions in clinical operations and outsourcing at major pharmaceutical and biotech companies. He is the founder and president of Clin.AI, a startup revolutionizing vendor selection and management in the industry.

2. KO's Background: KO's academic background includes a degree in electrical engineering and a master's in biomedical engineering. He started his career in pre-clinical animal work and transitioned to clinical operations in the pharmaceutical industry.

3. The Problem Clin.AI Addresses: Clin.AI focuses on solving the problem of vendor selection and management, particularly for organizations with budgets in the range of $40-50 million. Traditional methods using Excel files can be time-consuming and inefficient.

4. How Clin.AI Helps: Clin.AI provides a platform that streamlines vendor selection by quickly analyzing vendor proposals, facilitating negotiation, and aiding in the selection of the best vendor based on both price and quality. This platform can save organizations significant time and effort.

5. KO's Philosophy: KO emphasizes the importance of spending time with people to understand their problems and potential solutions. He also highlights the significance of being forward-looking and adding value to clients' experiences.

Send us Fan Mail

• Susan Stipa, with a diverse background in pharmaceuticals, biotechnology, and financial services, discusses the evolution of her career and her transition into marketing, emphasizing her passion for blending scientific understanding with creative communication.

• She highlights the rapid and transformative advancements in biopharmaceuticals, touching on the challenges and excitement surrounding emerging therapies like cell and gene therapy and expressing concern about ensuring access to these innovations.

• Susan mentions the importance of effective communication within the biotech industry, especially when engaging with journalists to accurately relay complex scientific concepts, showcasing CG Life’s role as a mediator to foster better understanding.

• She reflects on valuable leadership advice received from her father about making a strong initial impression and the importance of human connection, opposing a rigid corporate mentality, to foster creativity and meaningful relationships.

• Both Susan and the host, Don, share an appreciation for the relentless drive within the biotech industry and its potential to address global health challenges, emphasizing the fulfillment derived from their roles in this dynamic field.

Send us Fan Mail

Today on the Life Science Success Podcast, we have a very special guest with us—David Hibbard, the Vice President of Engineering at Sunrise Labs. With over 25 years of experience in medical device development, David has been at the forefront of innovation in areas ranging from Stress Echocardiography to Robotics.

• The interview features David Hibbard, VP of Engineering at Sunrise Labs, who has over 25 years of experience in medical device development. He holds a biomedical engineering degree from Boston University.

• Sunrise Labs specializes in Class II and Class III medical devices and focuses on end-to-end service, from software to hardware. The team size is just under 100 people, with approximately 70 to 80 engineers.

• David discusses the importance of strong project management, emphasizing the need to understand regulatory strategy and timelines, and advises that good client relationships are formed through transparency and integration, even in daily scrums.

• On the topic of leadership, David mentions the importance of good integrity and communication for long-term partnerships. He emphasizes that understanding the end user's needs is crucial for successful medical device development.

• Hibbard also talks about the use of AI to improve code robustness and mentions some of the challenges they are facing with remote work and maintaining a work-life balance in the current environment.

Send us Fan Mail

In this episode of the Life Science Success Podcast my guest is Dr. Vibhor Gupta.  Dr. Gupta is the Director and Founder at PangaeaData.AI. He trained in oncology research and has a breadth of experience in life sciences through his work in industry and academia over the last two decades.

1. Dr. Vibhor Gupta is the Director and Founder of PangaeaData.AI. He has a background in oncology research and a breadth of experience in life sciences.

2. Dr. Gupta's journey in the Life Sciences industry began when he realized the importance of combining scientific knowledge with computer programming skills to make sense of medical data, especially in the context of improving patient outcomes and advancing scientific research.

3. He emphasized the importance of motivation in pursuing a career in life sciences and how it helps individuals weather challenges and stay focused on their goals.

4. Dr. Gupta discussed his experience working in Silicon Valley with Quantum Secure, where he gained valuable insights into product development, customer behavior, and innovation in the tech industry.

5. Pangaea Data's focus is on leveraging artificial intelligence to connect undiagnosed patients with appropriate treatments and clinical trials, benefiting patients, clinicians, and pharmaceutical companies. They have demonstrated success in finding previously undiagnosed patients and reducing treatment costs.

Send us Fan Mail

In this episode of the Life Science Success Podcast, we're honored to have Dr. Alan Trounson, the CEO of Cartherics Pty Ltd, a company at the forefront of redefining cancer treatment through immunotherapy. Tune in as we discuss the future of cancer treatment, and much more!"

• Dr. Alan Trounson, CEO of Cartherics Pty Ltd, has a rich background in reproductive sciences and stem cell research. He has been instrumental in the development of human IVF and embryonic stem cells, and has also led the California Institute for Regenerative Medicine with a $3 billion budget.

• Cartherics aims to redefine cancer treatment through immunotherapy. The company is working on off-the-shelf CAR-T therapies that are designed to be low-cost and widely accessible, aiming to make cancer a manageable condition rather than a terminal one.

• The company differentiates itself by focusing on overcoming immune inhibitors in solid tumors and recruiting the patient's own immune system for a more effective treatment. They are also involved in gene editing to extend the life of CAR-T cells and make them more effective.

• Cartherics is in discussions with the FDA and plans to enter clinical trials by 2025. They are also collaborating with various international partners, including companies in Korea, China, Malaysia, and Australia, to bring in innovative ideas and technologies.

• Dr. Trounson is enthusiastic about the science and the potential impact of their work. He believes that getting the science right is crucial for achieving the expected outcomes and is excited about the broader scientific developments in the field.

Send us Fan Mail

In this episode of Life Science Success, my guest is Gaurav Kapoor.  Gaurav is a co-founder of Indegene, a digital-first life sciences commercialization company with 19 of the world's top 20 biopharma companies as clients. Gaurav is an expert in life sciences commercialization, having pioneered the co-commercialization model at Indegene. He has close to 25 years of experience in the technology-led healthcare solutions space.

• Don Davis: Host of the Life Science Success Podcast, focuses on strategy, people, process, and technology in life sciences. He also has a weekly series on LinkedIn Live about scaling organizations.
• Gaurav Kapoor: Co-founder of Indegene, a digital-first life sciences commercialization company. They work with 19 of the world's top 20 biopharma companies.

• Gaurav Kapoor: Shares his 25-year journey with Indegene. Initially focused on bridging the knowledge gap between doctors and the pharma industry using data and technology. They digitized thousands of hours of content from medical conferences.

• Indegene initially focused on B2C but shifted to a B2B model. They also moved their focus to the U.S. market due to its innovation and concentration of pharma companies.

• Significant industry changes around 2010 due to the patent cliff led to a focus on centralization and compliance.
• Indegene started reimagining the sales and marketing model around 2015, predicting a shift towards an omni-channel approach.

• Indegene pioneered co-commercialization, focusing on an omni-channel sales model and a "launch in a box" platform for mid-pharma and biotech companies. This allows for leaner, more efficient launches and operations.

• Both Don and Gaurav discuss the need for the industry to continue evolving, especially in the wake of the COVID-19 pandemic. They express hope that the new efficiencies and approaches adopted during the pandemic will become the new normal.

Send us Fan Mail

In this episode of Life Science Success, my guest is Brian DeDecker.  Brian is the CEO and co-founder of Seedling Biosystems in Boulder, Colorado. The planet’s ecosystems strain from current chemical and protein manufacturing methods and Brian co-founded Seedling to help solve this crisis. 

🔑 Key Takeaways:

1️⃣ Empathy in Communication: Whether talking to students or venture capitalists, understanding your audience's mindset is crucial. Brian shares how teaching has honed his skills in this area.

2️⃣ Sustainable Biomanufacturing: Seedling Biosystems aims to revolutionize industries by shifting processes to farming, particularly focusing on soybeans as a sustainable alternative.

3️⃣ Innovative Products: From baby formula proteins to squalene for vaccines, Seedling is working on products that not only meet market needs but do so in an eco-friendly manner.

4️⃣ Leadership Philosophy: "Do what you can with what you got, where you are." This Teddy Roosevelt quote serves as Brian's guiding principle, emphasizing resourcefulness.

5️⃣ Climate Change: Both a concern and a motivator, Brian believes that the challenges posed by climate change will bring out the best in humanity, driving us toward innovative solutions.

Send us Fan Mail

In this episode of the Life Science Success Podcast my guest is Brad Doerschuk, a visionary leader in clinical research with over 20 years of experience in pharmaceutical and biotech development. As the founder of PharmaMed Research and current President and CEO of InFocus Clinical Research, Brad has a proven track record of leading successful clinical development programs across multiple therapeutic areas and is a PharmaVoice 100 recipient.

00:00 Introduction to Life Science Success Podcast
00:34 Meet Brad Doerschuk: Visionary Leader in Clinical Research
01:22 Brad's Journey into Life Sciences
02:57 Founding a Research Organization
06:00 Challenges and Pivotal Moments in Drug Development
09:43 Specialization in Retina Diseases
18:54 Building and Leading High-Performing Teams
21:11 Merging Best Practices for Efficiency
22:48 The Role of Innovation in Clinical Trials
25:38 Leadership Advice and Personal Insights
31:11 Conclusion and Final Thoughts

Send us Fan Mail

Today on the Life Science Success podcast, my guest is Oksana Bovt.  Oksana is the founder of Theoria Creative, an agency that develops unique fundraising materials that enable biotech and life sciences clients to clearly and succinctly articulate their unique message and value when raising funds, soliciting partnerships, pitching at roadshows, or presenting to prospective buyers. Oksana was a previous guest, and we covered her company and, more broadly, the things Theoria Creative is working on. Today we are going to spend some time on scientific mechanisms of action.

1. Theoria Creative's Role:

   • Oksana explains that her agency helps companies build a compelling story to attract investment. They work closely with venture capitalists and investment bankers.

2. Challenges and Milestones:

   • Oksana shares her journey and the importance of pivoting and sensing industry needs. Feedback from clients helps them stay relevant.

3. Client Focus:

   • Theoria Creative mainly focuses on late preclinical and early clinical companies that are in constant need of fundraising.

4. Mechanisms of Action (MOA):

   • Oksana discusses the importance of clearly explaining the scientific mechanisms of action (MOA) to differentiate one company from another.

5. Communication Strategies:

   • Oksana outlines three steps for companies to clearly communicate their MOA:
     1. Outline the step-by-step process.
     2. Write a descriptive paragraph for each step.
     3. Compare the mechanism with the healthy and unhealthy state.

6. Materials and Outputs:

   • Theoria Creative produces pitch decks and animations, depending on the client's budget and stage.

7. Closing Remarks:

   • Both Don and Oksana emphasize the importance of clear communication in the life sciences sector for successful fundraising and partnerships.

This episode provides valuable insights into the importance of clear communication and storytelling in the life sciences sector, especially when it comes to explaining complex scientific mechanisms. Oksana's expertise in this area offers a roadmap for companies looking to articulate their value proposition effectively.

Send us Fan Mail

In this episode of Life Science Success, my guest is Dr. Jim Woody, CEO of 180 Life Sciences.Dr. Woody leads a pioneering team of scientific innovators at 180 Life Sciences, a clinical stage biotechnology company with three families of novel biologic drugs that address separate areas of inflammation, fibrosis and pain.

1. Background and Career: Dr. Jim Woody is a pediatric immunologist with a diverse career, including military service and venture capital experience. He was instrumental in the development of anti-TNF drugs, a class of biologics with a market value of about $40 billion per year.

2. Focus on Patient-Centricity: Dr. Woody emphasizes the importance of patient benefit in drug development. He served on the board of Stanford Children's Hospital and aims to develop therapies that significantly improve patients' lives.

3. Current Work at 180 Life Sciences: The company is focused on finding new indications for anti-TNF drugs. They are working on conditions like Dupuytren's contracture, frozen shoulder, and post-operative dementia, aiming to prevent disability and improve quality of life.

4. Challenges and Future Plans: Regulatory hurdles and clinical trials are the next steps for 180 Life Sciences. Dr. Woody estimates that drug approvals could take a couple of years, depending on feedback from agencies like the FDA.

5. Personal Insights: Dr. Woody advises aspiring professionals to seize new opportunities and emphasizes the role of luck in biotechnology. He is excited about the next generation of anti-inflammatory agents that could offer more targeted treatments.

Send us Fan Mail

In this episode of Life Science Success, my guest is Mike Martin, the CEO of CAI. CAI is a global professional services firm focused on engineering and quality consulting, Mike Martin guides a team of 800 individuals across the U.S., Europe, and APAC.

• Mike Martin shares his journey from being an engineering student at Purdue University to becoming the CEO of CAI. He emphasizes that his career was shaped by a series of choices based on guiding principles rather than a predetermined path to leadership.
• CAI focuses on areas like operational readiness, regulatory plans, and human performance but deliberately avoids facility and system design. They leverage their expertise in testing to guide clients through the complexities of launching new products.
• CAI has a global presence, allowing them to tap into a diverse pool of expertise and offer more comprehensive solutions to their clients. Being globally connected also helps them understand regional nuances in the life sciences industry.
• The company operates on an "owner's mindset," emphasizing that the growth of an owner's value is directly tied to the growth of the client's value. This philosophy is central to CAI's company culture.

Send us Fan Mail

In this episode of Life Science Success, my guest is Ravi Samavedam, the Chief Innovation Officer of Azzur Group. With over two decades of experience in the biotech and pharma industries, Ravi is a seasoned Biochemical Engineer who has worn many hats throughout his career. Prior to his current role, he served as the President of Azzur Cleanrooms on Demand™ and was also the General Manager of Azzur Boston. He's an expert in areas such as phase-appropriate cGMP implementation, process validation, and supplier management.

• Ravi Samavedam is the Chief Innovation Officer at Azzur Group, with over two decades of experience in the biotech and pharma industries. He transitioned from a biochemical engineer to his current role, having worked at companies like Baxter, Shire, and Amgen.

• His role at Azzur Group involves exploring potential growth areas for the company, such as their "Clean Rooms on Demand" business. This service aims to provide a flexible, cost-effective solution for companies in the biopharma sector, bridging the gap between traditional manufacturing options.

• Samavedam emphasizes the importance of innovation and impact in the healthcare industry. He believes that smaller, agile companies like Azzur can make a more significant impact compared to larger organizations where individual contributions may get diluted.

• One of the challenges he faces is educating the industry about new, more efficient models of operation. Traditional methods are often deeply ingrained, making it difficult for companies to see the value in innovative solutions like Azzur's.

• His leadership philosophy is "Don't let perfect get in the way of good," emphasizing the importance of practicality and risk mitigation in the pursuit of excellence. He is excited about the future of personalized medicine and believes that technology will continue to reduce inherent risks in biopharma processes.

Send us Fan Mail

In this episode of Life Science Success, my guest is RJ Kedziora, the co-founder of Estenda Solutions. With a career spanning over 30 years, RJ is a leading expert in healthcare technology and data analytics. We'll dive into his journey, the transformative work Estenda Solutions is doing, and the future of digital health.

• The podcast "Life Science Success" hosted by Don, a consultant in life sciences, features RJ Kedziora, the co-founder of Estenda Solutions, a company specializing in healthcare technology and data analytics.
• RJ Kedziora has a career spanning over 30 years and started Estenda Solutions in 2003 with Drew Lewis. The company initially focused on diabetes but has since expanded into other chronic conditions, offering solutions for Fortune 50 companies, startups, and government agencies.
• Estenda Solutions is unique in that it focuses on innovative product development, particularly in data analytics. They work with clients who have an idea but are not entirely sure how to execute it, rather than those who know exactly what they want.
• The company is ISO 13485 certified, indicating a strong quality assurance program. They take on larger projects and are audited annually to ensure they maintain high-quality processes.
• RJ Kedziora emphasizes the importance of data in healthcare, noting that the industry has evolved from having minimal data to dealing with billions of records. He is excited about the potential of AI and machine learning but also cautious about the rapid pace of technological advancements.

Send us Fan Mail

In this episode of Life Science Success, my guest is Hanns-Christian Mahler.  Dr. Mahler is Founder, CEO and Board Member at Ten23 health AG, the human-centric and sustainable pharmaceutical development partner.

1. Hanns-Christian Mahler is the Founder, CEO, and Board Member of ten23 health AG, a company specializing in sustainable pharmaceutical development. He has a background in pharmacy and has worked in various pharmaceutical companies and CDMOs (Contract Development and Manufacturing Organizations).

2. Mahler's leadership style focuses on building organizations from the ground up, emphasizing the importance of values, purpose, and motivation. He believes in creating a work environment that fosters joy and engagement among employees.

3. ten23 health AG differentiates itself from other CDMOs by its customer-centric approach and specialized expertise in developing difficult-to-produce products, such as high-volume blockbuster injectable products and products for subcutaneous self-administration.

4. Mahler is deeply concerned about climate change and is inspired by young activists like Greta Thunberg. His company is committed to sustainability, even registering for B Corp pending status and implementing various eco-friendly initiatives.

5. The best leadership advice Mahler has received emphasizes trust in employees. He believes that if you have the right people, there's no need to micromanage, and that trust fosters a more productive and engaged workforce.

Send us Fan Mail

In this episode of the Life Science Success Podcast, my guest is Lisa Sellers, PhD.   Dr. Sellers is the CEO of Vector Laboratories. She is an innovative and impactful leader with a truly unique approach to leading teams. She has deep expertise in running global life science tools businesses, developing new business strategies, and demonstrating excellent execution by leveraging her leadership style to harness the value of talent.

• The episode features Lisa V. Sellers, PhD, who is the CEO of Vector Laboratories. The discussion aims to explore Lisa's career journey, her role as CEO, and the future of life sciences.

• Lisa V. Sellers has been in the life sciences industry for over two decades. She has held various roles, from being a product manager in smaller businesses to being the CEO of Vector Laboratories. She is passionate about understanding the intricacies of the business she leads, as well as the needs of the customers they serve. She believes in leveraging innovation to meet these needs and enjoys developing multi-year growth strategies with her teams.

• Vector Laboratories is a company that specializes in bioconjugation, a technical capability that allows them to serve customers in various sectors like drug development, diagnostics, and life science tools. The company has been around for 45 years and is currently in a unique position where it combines the stability of a mature portfolio with the agility and growth potential of a startup.

• One of the key challenges Lisa faces as a CEO is managing people's ability to adapt to change, especially in a rapidly evolving industry. To tackle this, she has implemented comprehensive onboarding programs for new hires and emphasizes the importance of mentoring and community engagement. She also collaborates with local schools for community service, blending it with coaching and mentoring to broaden perspectives.

• Lisa is particularly excited about the future convergence of genomics and proteomics in life sciences. She sees this as a significant step toward a more integrated understanding of biology. She also believes that the key to navigating the future successfully is to be flexible and open to possibilities. She expresses concern about whether people and organizations will be able to adapt quickly enough to the changes that are bound to come in the field of life sciences.

Send us Fan Mail

In this episode of Life Science Success, my guest is Rajeev Sehgal.  Rajeev is the Sr. Director of Informatics at Azenta Life Sciences.  Rajeev is responsible for development and execution of Informatics strategy including product management, development, SQA, delivery, and support.

• Rajeev Sehgal discusses his experience with developing strategies that can be executed effectively. He highlights the importance of not only thinking about strategy but also having a clear understanding of how to execute it.
• Sehgal emphasizes the significance of focusing on the process rather than solely on the results. He notes that if the steps are right and repeatable, the results will show up eventually.
• Sehgal advises new leaders to be kind to themselves and not put too much pressure on themselves to deliver right away, especially in a new role or organization.
• He expresses concern about people hiding behind processes to stop progress and analysis paralysis, where people want more data than necessary before making a decision.
• Sehgal finds inspiration in doing something that will have a patient impact, working with colleagues who are doing amazing work, and seeing his children grow.

Key takeaways:

• Strategies must lead to good execution paths for their value to be realized.
• Focusing on the process and making it repeatable is key to achieving results.
• New leaders should be kind to themselves and not put too much pressure on themselves to deliver right away.
• People should not hide behind processes to stop progress, and analysis paralysis should be avoided.
• Doing something that will have a patient impact and working with colleagues who are doing amazing work can be inspiring.

Send us Fan Mail

In this episode of Life Science Success, my guest is Meredith Manuel.  Ms. Manuel is a proven leader with drive and determination in the scientific industry, specializing in global drug development and project management.  

Key Takeaways:

• Introduction to Meredith Manuel: Meredith Manuel is an accomplished leader with extensive experience in the scientific industry, particularly in global drug development and project management.

• Focus on Life Sciences: The podcast features a conversation between Meredith Manuel and the host, Don, who is a consultant specializing in helping companies within the life sciences sector enhance their strategies, processes, and technologies.

• Exploring Spatial Biology: Meredith discusses her role at "enable" where she manages the commercial division of a company focused on spatial biology. Spatial biology involves analyzing markers and molecules in the context of tissue, allowing for a deeper understanding of cell interactions and disease mechanisms.

• Impact on Drug Development: The application of spatial biology in drug development is highlighted, emphasizing the importance of moving beyond traditional single biomarker approaches. Integrating various data sets and understanding complex interactions within tissues is seen as crucial for advancing drug development.

• Leadership and Collaboration: Meredith also shares insights about leadership and collaboration, encouraging individuals to advocate for themselves and promote diversity of perspectives. She emphasizes the need for open communication within teams and across disciplines, especially in the dynamic field of life sciences.

Details:

Meredith Manuel is introduced as a guest on the "Life Science Success Podcast." The podcast is hosted by Don, a life sciences consultant focusing on improving companies' strategies, processes, and technology within the life sciences sector. Meredith has a strong background in the scientific industry, with a focus on global drug development and project management. She has a lifelong fascination with science, dating back to kindergarten when she first became interested in the field. Her career has spanned different areas of drug development, and she is particularly passionate about spatial biology, a cutting-edge technology that involves analyzing markers and molecules in tissue context.

Meredith's role at "enable" involves managing the commercial division of a company that specializes in spatial biology. She explains that spatial biology allows researchers to analyze cell interactions and disease mechanisms by studying markers in the context of tissue. This technology enables a more comprehensive understanding of disease processes and has applications in challenging areas like oncology and immunology. Meredith emphasizes that this approach goes beyond the traditional single biomarker paradigm, enabling a deeper understanding of complex biological processes.

Meredith discusses leadership and collaboration, drawing from her extensive experience. She encourages individuals, especially women, to advocate for themselves and share their ideas openly. She shares a story about a female boss who advised her to be her own advocate and speak up. She believes that diverse perspectives are crucial for innovation and problem-solving. Meredith underscores the importance of listening, collaboration, and communication in achieving successful outcomes within teams.

The conversation concludes with discussions about the challenges and potential future directions of spatial biology and drug development. Meredith expresses her desire to contribute to improving the h

Send us Fan Mail

In this episode of Life Science Success, I am interviewing one of the world’s leading business thinkers, Dr. David Burkus’ forward-thinking ideas and bestselling books are helping leaders build their best team ever.

• Dr. David Burkus discusses the challenges of remote and hybrid work environments and the importance of deliberate leadership
• He emphasizes the need for fair feedback, giving feedback in proportion to how someone is doing
• Dr. Burkus also stresses the importance of micro praises and the need to be deliberate about recognizing employees' successes
• He believes that many organizations are approaching remote and hybrid work in the wrong way and need to have a broader conversation about the type of work that should happen in the office versus remotely
• Dr. Burkus is inspired to make work not suck and wants to help organizations tap into their employees' potential
• He also discusses his course, "Build Your Best Team Ever," which provides research-based actions for team leaders to improve their teams' dynamics and productivity

Send us Fan Mail

In this episode of the Life Science Success Podcast my guest is Christopher Duma, a board-certified neurosurgeon who is pioneering innovative treatments for neurodegenerative diseases at Regeneration Biomedical, Inc.

00:00 Introduction to Life Science Success Podcast
00:34 Meet Dr. Christopher Duma: A Pioneer in Neurosurgery
00:59 Dr. Duma's Journey to Neurosurgery
03:13 Challenges in Treating Neurodegenerative Diseases
05:59 The Potential of Stem Cells in Neurosurgery
10:06 Technological Advances in Neurosurgery
13:34 Innovations in Deep Brain Stimulation
15:57 Exploring Immunotherapy and Gene Therapy
18:14 The Mission of Regeneration Biomedical
20:15 Understanding Stem Cell Therapy for Brain Diseases
27:28 FDA Trials and Initial Research
28:07 Innovative Stem Cell Injection Method
30:20 Phase One Trial and Results
34:20 Future of Stem Cell Treatments
40:30 Challenges and Advancements in Movement Disorders
45:14 Leadership and Personal Insights
52:50 Conclusion and Final Thoughts

Send us Fan Mail

In this episode of Life Science Success, my guest is Ketan Mehta, the founder and CEO of Tris Pharma. Under his leadership, Tris Pharma has developed many innovative technologies, launched new products, and established itself as a leader among technology-driven pharmaceutical companies. 

• Ketan Mehta discusses the importance of being open to change and feedback in building successful companies
• Patient feedback has directly influenced Tris Pharma's product development
• Ketan Mehta believes that the pharmaceutical industry will evolve significantly in the next decade, particularly with the rise of personalized medicine and digital health
• He offers advice for aspiring entrepreneurs in the life sciences, emphasizing the need for clear motivation, commitment, and a focus on making a positive impact
• Ketan Mehta is excited about the future possibilities and the potential for significant change in the next few decades

Send us Fan Mail

This week on the Life Science Success podcast, my guest is Thomas Farb-Horch.  Thomas is the CEO of Thrive Bio.  He has been involved in the founding of 18 pharmaceutical, biotech, medtech, software, and AI companies, 7 of which have been unicorns. Currently, he is CEO and Co-Founder of Boston-based Thrive Bioscience, which commercializes instruments and software for a critically important but neglected area of life sciences, which is imaging, analytics, and automation of cell culture, cell-based research, and cell therapeutics.

• Thomas Forest Farb-Horch has experience automating cytology labs and now seeks to improve cell culture labs through Thrive.
• Thrive aims to improve the low chances of therapeutics getting from bench to patient by transforming cell biology.
• Thrive's technology collects large, comparable data sets that make better cells, which is important for bringing cell therapeutics to the market.
• Thrive's data sets and images are valuable to researchers because they can see things that they never saw before and make faster decisions.
• Thrive is transforming viral plaque assay, which is the standard way of studying viruses, and can now track plaques from day 2 instead of waiting for weeks.
• Thomas is concerned about divisiveness, duality, and false dualities, and the lack of equality of opportunity, education, and health.
• Thomas is excited about solving big, ignored problems and changing the world.

Send us Fan Mail

In this episode of the Life Science Success Podcast, my guest is Artem Britchenko.  Artem is the CEO of Platforce, which helps companies that interact with healthcare professionals and care about the efficiency and compliance of these interactions. He has been working in the B2C Pharma industry, helping companies improve their sales force effectiveness, customer engagement, and customer centricity.

• Don Davis, PhD, MBA interviews Artem Brytchenko, CEO of Platforce
• Platforce is a CRM solution tailored to the unique needs of the life sciences industry
• The solution includes closed loop marketing, remote capabilities, consent collection, distributor order optimization, and more
• The biggest challenges faced by Platforce include constant innovation and adaptation, scaling operations, and managing a global, distributed team
• The biggest opportunities include the rapid digital transformation of the life sciences industry, expanding to new geographies and markets, and serving adjacent sectors within healthcare
• Artem is inspired by his team, challenges, and family, concerned about the rapidly changing technological landscape and global complexities, and excited about fostering innovation and collaboration, technological advancements, and personal growth and happiness